| ID | 1238 |
| Name of the vaccine | TB/FLU-01L |
| Microbe | Bacteria |
| Disease name | Pulmonary Tuberculosis (TB) |
| Name of bacteria | Mycobacterium tuberculosis |
| Type of vaccine | Viral vector |
| Nucleic acid content | DNA |
| Age | 18 to 50 years |
| Description of the vaccine | Replication-deficient recombinant influenza virus A expressing ESAT-6 antigen. |
| Name of the manufacturer | Research Institute for Biological Safety Problems |
| Name of the manufacturing country | Kazakhstan |
| Year of manufacture | 2015 |
| Clinical Phase status | Clinical - Phase 1 |
| Bacterial strain | Acid-fast Gram-positive bacteria. |
| Efficacy | 72.2% from the sublingual group and 77.8% from the immunized intranasal group. |
| Vaccine formulation | NA |
| Dosage | Two doses at day 1 and 21. |
| Mechanism of action | Strong local cytokine production associated with respiratory immune cell trafficking. |
| Route of administration | Intranasal |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Nasal congestion, sneezing, fever, sore throat and pharynx hyperaemia. |
| Post vaccination | NA |
| Dose type | Combination (2 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT03017378 |
| Reference | https://tbvaccinesforum.org/wp-content/uploads/2018/03/5GF-Breakout-2-Stukova.pdf |
| Other name | NA |
| Additional Links | https://www.mdpi.com/2076-3417/11/19/9250/pdf
|